Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?
Ryan A BalkoAndrea Wahner HendricksonMegan E GrudemCarolyn M KlampeAminah JatoiPublished in: The American journal of hospice & palliative care (2018)
The PARP inhibitors merit further study for chemotherapy-induced peripheral neuropathy. For patients suffering from peripheral neuropathy, these putative palliative effects might prompt earlier consideration of a PARP inhibitor as part of cancer treatment.